Cite
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
MLA
Tai-Jan Chiu, et al. “Liposomal Irinotecan Pre-Emptive Dose Reduction in Patients with Pancreatic Ductal Adenocarcinoma: 667 Patients’ Experience within a Population-Based Study.” Therapeutic Advances in Medical Oncology, vol. 13, Nov. 2021. EBSCOhost, https://doi.org/10.1177/17588359211058255.
APA
Tai-Jan Chiu, Yung-Yeh Su, Shih-Hung Yang, Chung-Pin Li, Li-Yuan Bai, Nai-Jung Chiang, Shih-Chang Chuang, Yan-Shen Shan, De-Chuan Chan, Li-Tzong Chen, Chia-Jui Yen, Cheng-Ming Peng, Yen-Yang Chen, Jen-Shi Chen, & Wen-Chi Chou. (2021). Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study. Therapeutic Advances in Medical Oncology, 13. https://doi.org/10.1177/17588359211058255
Chicago
Tai-Jan Chiu, Yung-Yeh Su, Shih-Hung Yang, Chung-Pin Li, Li-Yuan Bai, Nai-Jung Chiang, Shih-Chang Chuang, et al. 2021. “Liposomal Irinotecan Pre-Emptive Dose Reduction in Patients with Pancreatic Ductal Adenocarcinoma: 667 Patients’ Experience within a Population-Based Study.” Therapeutic Advances in Medical Oncology 13 (November). doi:10.1177/17588359211058255.